Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Evan Hatfill

Physician Assistant, Medical Nashville, TN Physician Assistant

NPI 1679175996 CMS profile 10501083

3520 Fair Meadows Dr, Nashville, TN 37211

Open in the dashboard

General payments

$17,783

578 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Evan Hatfill of Nashville, TN is reported in the CMS Open Payments database as having received $17,783 across 578 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,838 128
2024 General $2,986 103
2023 General $4,048 135
2022 General $5,820 185
2021 General $1,091 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evan Hatfill
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Evan Hatfill were reported at $3,838. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Evan Hatfill Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,091 $156 $41–$563 $132
2022 $5,820 $185 $55–$649 $149
2023 $4,048 $199 $58–$717 $160
2024 $2,986 $206 $62–$740 $164
2025 $3,838 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,640 88 payments
  2. Sun Pharmaceutical Industries Inc. $2,072 62 payments
  3. Novartis Pharmaceuticals Corporation $2,020 78 payments
  4. Janssen Biotech, Inc. $1,744 67 payments
  5. Lilly USA, LLC $1,320 28 payments
  6. Regeneron Healthcare Solutions, Inc. $1,293 46 payments
  7. E.R. Squibb & Sons, L.L.C. $937 24 payments
  8. Incyte Corporation $914 28 payments
  9. Genzyme Corporation $765 21 payments
  10. LEO Pharma Inc. $762 28 payments
  11. Other $3,317 108 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,231 570 payments
  2. Education $552 8 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,071 71 payments
  2. ILUMYA $1,779 59 payments
  3. SKYRIZI $1,494 47 payments
  4. DUPIXENT Immunology $1,146 34 payments
  5. COSENTYX $1,104 42 payments
  6. OPZELURA $914 28 payments
  7. DUPIXENT Inflammation And Immunology $900 32 payments
  8. SOTYKTU $802 22 payments
  9. ADBRY $714 26 payments
  10. RINVOQ $606 18 payments
  11. Other $5,833 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$6,372

Medicare's payments for the services billed

Medicare patients

40

Average age 74

Services billed

254

17 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 45%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $560
$560 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $453
$453 — —
SKYRIZI
  • AbbVie, Inc. $390
$390 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $348
$348 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $246
$246 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

578 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record